{"id":"arterolane-piperaquine-mefloquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL172","moleculeType":"Small molecule","molecularWeight":"378.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Arterolane (a semi-synthetic artemisinin derivative) rapidly reduces parasite biomass by generating reactive oxygen species and damaging parasite membranes. Piperaquine, a bisquinoline, concentrates in parasites and inhibits heme polymerization, causing toxic accumulation. Mefloquine acts synergistically by disrupting parasite mitochondrial function and metabolism. The triple combination targets multiple pathways to reduce treatment duration and prevent resistance.","oneSentence":"A triple artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms: artemether (artemisinin derivative) damages parasite membranes, piperaquine accumulates in parasites and disrupts hemoglobin digestion, and mefloquine interferes with parasite metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:30.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated Plasmodium falciparum malaria"},{"name":"Malaria in endemic regions (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT03452475","phase":"PHASE3","title":"Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-07","conditions":"Plasmodium Falciparum","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Arterolane-piperaquine+mefloquine","genericName":"Arterolane-piperaquine+mefloquine","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A triple artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms: artemether (artemisinin derivative) damages parasite membranes, piperaquine accumulates in parasites and disrupts hemoglobin digestion, and mefloquine interferes with parasite metabolism. Used for Uncomplicated Plasmodium falciparum malaria, Malaria in endemic regions (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}